Neumora Therapeutics, Inc. (NMRA)

9,67 +0,04 (+0,42%) Alla chiusura: 04:00PM EDT

Neumora Therapeutics, Inc.

490 Arsenal Way
Suite 200
Watertown, MA 02472
United States
857 760 0900
https://www.neumoratx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 120

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Paul L. Berns	Co-Founder & Executive Chairman	1,65M	N/D	1967
Mr. Henry O. Gosebruch	President, CEO & Director	3,33M	N/D	1973
Mr. Jason G. Duncan	Chief Legal Officer	315k	N/D	1974
Mr. Robert Lenz M.D., Ph.D.	Head of Research & Development	770,29k	N/D	1971
Ms. Carol Suh	Co-Founder & COO	N/D	N/D	1990
Dr. Robert Michael Poole FACP, M.D.	Co-Founder & Advisor	N/D	N/D	1957
Dr. Joshua Pinto Ph.D.	Chief Financial Officer	876,64k	N/D	1985
Mr. Michael Lee Milligan	Principal Accounting Officer	N/D	N/D	N/D
Dr. Rajesh Manchanda Ph.D.	Chief Technical Operations Officer	N/D	N/D	1966
Mr. Nicholas Brandon Ph.D.	Chief Scientific Officer	N/D	N/D	1974

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Neumora Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.